secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0001437749-25-006832
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed announces positive Phase 2b extension results for neflamapimod in DLB
------------------------------------------------------------------------------

- New capsule batch yielded higher plasma levels; CDR-SB improved vs old capsules (p<0.001) and vs placebo (p=0.003).
- CGIC score improved with new capsules vs old (4.02 vs 4.46, p=0.035); within-subject placebo comparison also significant (p=0.035).
- Fall incidence lower with new capsules (7.4%) vs old (14.5%) and vs placebo (18.8%, p=0.04); in ptau181 <2.2 subgroup: 4.0% vs 19.7% (p=0.007).
- 149 patients entered extension; 94 received new capsules; completion rates 87.3% (old) and 91.5% (new); no new safety signals.
- Company plans to complete full 32-week extension and discuss Phase 3 plans with regulators later this year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774925006832/0001437749-25-006832-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774925006832/crvo20250310_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-006832

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer